CL2016001940A1 - Composición farmacéutica que contiene un compuesto derivado de imidazo[1,5-a]indol, [1,2,4]triazolo[3,4-a]isoindol, [1,2,3]triazolo[5,1-a]isoindol ó 1,4-dihidroindeno[1,2-c] sustituidos y un segundo agente terapéutico; y su uso tratar la inmunosupresión mediada por indoleamina 2,3-dioxigenasa (ido), estimular la proliferación de células t, inhibir la degradación de triptófano en células que expresa ido, para tratar una enfermedad asociada con ido como una infección o cáncer (divisional de solicitud n° 2649-2015). - Google Patents
Composición farmacéutica que contiene un compuesto derivado de imidazo[1,5-a]indol, [1,2,4]triazolo[3,4-a]isoindol, [1,2,3]triazolo[5,1-a]isoindol ó 1,4-dihidroindeno[1,2-c] sustituidos y un segundo agente terapéutico; y su uso tratar la inmunosupresión mediada por indoleamina 2,3-dioxigenasa (ido), estimular la proliferación de células t, inhibir la degradación de triptófano en células que expresa ido, para tratar una enfermedad asociada con ido como una infección o cáncer (divisional de solicitud n° 2649-2015).Info
- Publication number
- CL2016001940A1 CL2016001940A1 CL2016001940A CL2016001940A CL2016001940A1 CL 2016001940 A1 CL2016001940 A1 CL 2016001940A1 CL 2016001940 A CL2016001940 A CL 2016001940A CL 2016001940 A CL2016001940 A CL 2016001940A CL 2016001940 A1 CL2016001940 A1 CL 2016001940A1
- Authority
- CL
- Chile
- Prior art keywords
- gone
- triazolo
- treat
- isoindole
- indoleamine
- Prior art date
Links
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title abstract 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title abstract 4
- BSZGFXNZRDBQDL-UHFFFAOYSA-N 1h-imidazo[1,5-a]indole Chemical compound C1=CC=C2N3CN=CC3=CC2=C1 BSZGFXNZRDBQDL-UHFFFAOYSA-N 0.000 title abstract 2
- KOERXBHXXBPBKA-UHFFFAOYSA-N 2,4-dihydro-1h-indene Chemical class C1=CCC2=CCCC2=C1 KOERXBHXXBPBKA-UHFFFAOYSA-N 0.000 title abstract 2
- WWEOFPSPWGRBCB-UHFFFAOYSA-N 3H-[1,2,4]triazolo[3,4-a]isoindole Chemical compound C1N=Nc2n1cc1ccccc21 WWEOFPSPWGRBCB-UHFFFAOYSA-N 0.000 title abstract 2
- 206010062016 Immunosuppression Diseases 0.000 title abstract 2
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006052 T cell proliferation Effects 0.000 title 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 125000000904 isoindolyl group Chemical class C=1(NC=C2C=CC=CC12)* 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- YQRBAEULFKTKCY-UHFFFAOYSA-N 3h-triazolo[5,1-a]isoindole Chemical compound C1=CC=CC2=C3C=NNN3C=C21 YQRBAEULFKTKCY-UHFFFAOYSA-N 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSICIÓN FARMACÉUTICA QUE CONTIENE UN COMPUESTO DERIVADO DE IMIDAZO[1,5-A]INDOL, [1,2,4]TRIAZOLO[3,4-A]ISOINDOL, [1,2,3]TRIAZOLO[5,1-A]ISOINDOL Ó 1,4-DIHIDROINDENO[1,2-C] SUSTITUIDOS Y UN SEGUNDO AGENTE TERAPÉUTICO; Y SU USO TRATAR LA INMUNOSUPRESIÓN MEDIADA POR INDOLEAMINA 2,3-DIOXIGENASA (IDO), ESTIMULAR LA PROLIFERACIÓN DE CÉLULAS T, INHIBIR LA DEGRADACIÓN DE TRIPTÓFANO EN CÉLULAS QUE EXPRESA IDO, PARA TRATAR UNA ENFERMEDAD ASOCIADA CON IDO COMO UNA INFECCIÓN O CÁNCER (DIVISIONAL DE SOLICITUD N° 2649-2015).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784089P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001940A1 true CL2016001940A1 (es) | 2017-03-10 |
Family
ID=50686105
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002649A CL2015002649A1 (es) | 2013-03-14 | 2015-09-11 | Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano |
| CL2016001940A CL2016001940A1 (es) | 2013-03-14 | 2016-08-01 | Composición farmacéutica que contiene un compuesto derivado de imidazo[1,5-a]indol, [1,2,4]triazolo[3,4-a]isoindol, [1,2,3]triazolo[5,1-a]isoindol ó 1,4-dihidroindeno[1,2-c] sustituidos y un segundo agente terapéutico; y su uso tratar la inmunosupresión mediada por indoleamina 2,3-dioxigenasa (ido), estimular la proliferación de células t, inhibir la degradación de triptófano en células que expresa ido, para tratar una enfermedad asociada con ido como una infección o cáncer (divisional de solicitud n° 2649-2015). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002649A CL2015002649A1 (es) | 2013-03-14 | 2015-09-11 | Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9617272B2 (es) |
| EP (2) | EP2976332B1 (es) |
| JP (2) | JP6093903B2 (es) |
| KR (1) | KR20150126623A (es) |
| CN (1) | CN105189466A (es) |
| AU (2) | AU2014241079C1 (es) |
| BR (1) | BR112015022588A2 (es) |
| CA (1) | CA2902174A1 (es) |
| CL (2) | CL2015002649A1 (es) |
| CR (1) | CR20150485A (es) |
| HK (1) | HK1213259A1 (es) |
| IL (1) | IL241027A0 (es) |
| MA (1) | MA38493B1 (es) |
| MX (1) | MX361375B (es) |
| PE (1) | PE20151593A1 (es) |
| PH (1) | PH12015501866A1 (es) |
| RU (1) | RU2667509C2 (es) |
| SA (1) | SA515361127B1 (es) |
| SG (2) | SG11201507255QA (es) |
| UA (1) | UA118103C2 (es) |
| WO (1) | WO2014159248A1 (es) |
| ZA (1) | ZA201607948B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485705B2 (en) | 2015-07-24 | 2022-11-01 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| US10053463B2 (en) | 2013-03-14 | 2018-08-21 | Janssen Pharmaceutica Nv | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
| SG11201507382QA (en) | 2013-03-14 | 2015-10-29 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| WO2014152589A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| CN103570727B (zh) | 2013-11-12 | 2015-08-19 | 复旦大学 | 一种n-苄基色胺酮衍生物及其制备方法和应用 |
| JP6680766B2 (ja) | 2014-09-05 | 2020-04-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 癌治療のためのインドール−アミン−２，３−ジオキシゲナーゼ（ｉｄｏ）拮抗薬としてのシクロヘキシル−エチル置換ジアザ及びトリアザ三環化合物 |
| EP3511331A1 (en) | 2014-09-12 | 2019-07-17 | Boehringer Ingelheim International GmbH | Spirocyclic inhibitors of cathepsin c |
| EA034015B1 (ru) | 2014-09-12 | 2019-12-19 | Янссен Фармацевтика Нв | Модуляторы р2х7 |
| GB201417369D0 (en) * | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| JP6701214B2 (ja) * | 2014-11-03 | 2020-05-27 | イオメット ファーマ リミテッド | 医薬化合物 |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| TWI698435B (zh) * | 2015-04-10 | 2020-07-11 | 英屬開曼群島商百濟神州有限公司 | 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶 |
| WO2016165613A1 (en) | 2015-04-12 | 2016-10-20 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as ido and tdo inhibitors |
| EP3294732B1 (en) * | 2015-05-15 | 2019-09-25 | Gilead Sciences, Inc. | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
| GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
| CN105037371A (zh) * | 2015-06-30 | 2015-11-11 | 西华大学 | 一种氘代的吲哚胺-2,3-双加氧酶抑制剂 |
| EP3394068A4 (en) | 2015-12-24 | 2019-07-03 | Genentech, Inc. | TDO2 INHIBITORS |
| CN107056785B (zh) * | 2016-01-02 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为ido和tdo抑制剂的杂环化合物 |
| US20190031665A1 (en) * | 2016-02-02 | 2019-01-31 | Emcure Pharmaceuticals Limited | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer |
| WO2017140274A1 (zh) * | 2016-02-19 | 2017-08-24 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| WO2017140272A1 (zh) * | 2016-02-19 | 2017-08-24 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| WO2017149469A1 (en) | 2016-03-03 | 2017-09-08 | Emcure Pharmaceuticals Limited | Heterocyclic compounds useful as ido and/or tdo modulators |
| BR112018071602B1 (pt) * | 2016-04-29 | 2024-02-27 | Iomet Pharma Ltd. | Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase |
| WO2017198159A1 (zh) * | 2016-05-16 | 2017-11-23 | 鲁南制药集团股份有限公司 | 含桥环的咪唑衍生物 |
| CN107383012B (zh) * | 2016-05-16 | 2021-09-28 | 鲁南制药集团股份有限公司 | 含二环的咪唑醇衍生物 |
| CN107663159A (zh) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| US11607426B2 (en) | 2016-09-19 | 2023-03-21 | University Of South Florida | Method of targeting oncolytic viruses to tumors |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| EP3515914A4 (en) * | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES |
| EP4190335A1 (en) | 2016-10-13 | 2023-06-07 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| CN108884099B (zh) * | 2016-10-21 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 |
| CN108203438B (zh) | 2016-12-20 | 2021-09-28 | 深圳微芯生物科技股份有限公司 | 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物 |
| ES2970715T3 (es) | 2016-12-22 | 2024-05-30 | Prec Pharmaceuticals Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| US11603373B2 (en) | 2017-06-28 | 2023-03-14 | Genentech, Inc. | TDO2 and IDO1 inhibitors |
| EP3645537A1 (en) | 2017-06-28 | 2020-05-06 | Genentech, Inc. | Tdo2 and ido1 inhibitors |
| CN109384791B (zh) * | 2017-08-09 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法 |
| WO2019054465A1 (ja) * | 2017-09-15 | 2019-03-21 | 大鵬薬品工業株式会社 | Ｉｄｏの発現が関与する疾患の予防及び／又は治療剤 |
| US20200239452A1 (en) * | 2017-10-19 | 2020-07-30 | General Incorporated Association Pharma Valley Project Supporting Organization | IDO/TDO Inhibitor |
| WO2019101188A1 (en) | 2017-11-25 | 2019-05-31 | Beigene, Ltd. | Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases |
| KR20200106513A (ko) | 2018-01-05 | 2020-09-14 | 다이서나 파마수이티컬, 인크. | 면역요법을 강화시키기 위하여 베타-카테닌 및 ido 발현의 감소 |
| WO2019183145A1 (en) | 2018-03-20 | 2019-09-26 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| EP3856178A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
| MX2022003819A (es) | 2019-09-30 | 2022-05-11 | Janssen Pharmaceutica Nv | Ligandos de pet de mgl radiomarcados. |
| KR20220157999A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| EP4301358A2 (en) | 2021-03-05 | 2024-01-10 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH516573A (de) * | 1967-08-15 | 1971-12-15 | Sandoz Ag | Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen |
| US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US6395876B1 (en) | 1997-12-05 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
| CA2483451C (en) | 2002-04-12 | 2014-07-29 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| WO2003097609A1 (en) * | 2002-05-15 | 2003-11-27 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
| EP2260846B1 (en) | 2003-03-27 | 2018-11-28 | Lankenau Institute for Medical Research | Novel methods for the treatment of cancer |
| DE102007020493A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Amid-Derivate |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| WO2009132238A2 (en) | 2008-04-24 | 2009-10-29 | Newlink Genetics | Ido inhibitors |
| EP2365748A4 (en) * | 2008-11-13 | 2012-05-02 | Merck Sharp & Dohme | IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| JP2012037986A (ja) | 2010-08-04 | 2012-02-23 | Canon Inc | 画像形成装置及びその制御方法と画像形成システム |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 |
-
2014
- 2014-03-10 EP EP14722814.2A patent/EP2976332B1/en not_active Not-in-force
- 2014-03-10 MA MA38493A patent/MA38493B1/fr unknown
- 2014-03-10 PE PE2015001907A patent/PE20151593A1/es not_active Application Discontinuation
- 2014-03-10 AU AU2014241079A patent/AU2014241079C1/en not_active Ceased
- 2014-03-10 MX MX2015011385A patent/MX361375B/es active IP Right Grant
- 2014-03-10 SG SG11201507255QA patent/SG11201507255QA/en unknown
- 2014-03-10 BR BR112015022588A patent/BR112015022588A2/pt not_active Application Discontinuation
- 2014-03-10 JP JP2016501035A patent/JP6093903B2/ja not_active Expired - Fee Related
- 2014-03-10 RU RU2015143990A patent/RU2667509C2/ru not_active IP Right Cessation
- 2014-03-10 CA CA2902174A patent/CA2902174A1/en not_active Abandoned
- 2014-03-10 CN CN201480015368.3A patent/CN105189466A/zh active Pending
- 2014-03-10 WO PCT/US2014/022680 patent/WO2014159248A1/en active Application Filing
- 2014-03-10 KR KR1020157025259A patent/KR20150126623A/ko not_active Application Discontinuation
- 2014-03-10 EP EP18152869.6A patent/EP3366678A1/en not_active Withdrawn
- 2014-03-10 US US14/774,450 patent/US9617272B2/en not_active Expired - Fee Related
- 2014-03-10 SG SG10201707545XA patent/SG10201707545XA/en unknown
- 2014-10-03 UA UAA201510014A patent/UA118103C2/uk unknown
-
2015
- 2015-08-25 PH PH12015501866A patent/PH12015501866A1/en unknown
- 2015-09-01 IL IL241027A patent/IL241027A0/en unknown
- 2015-09-11 CL CL2015002649A patent/CL2015002649A1/es unknown
- 2015-09-14 SA SA515361127A patent/SA515361127B1/ar unknown
- 2015-09-14 CR CR20150485A patent/CR20150485A/es unknown
-
2016
- 2016-02-04 HK HK16101323.8A patent/HK1213259A1/zh not_active IP Right Cessation
- 2016-08-01 CL CL2016001940A patent/CL2016001940A1/es unknown
- 2016-11-14 JP JP2016221202A patent/JP6352368B2/ja not_active Expired - Fee Related
- 2016-11-17 ZA ZA2016/07948A patent/ZA201607948B/en unknown
-
2017
- 2017-02-16 US US15/434,414 patent/US9981973B2/en not_active Expired - Fee Related
- 2017-03-13 AU AU2017201693A patent/AU2017201693A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485705B2 (en) | 2015-07-24 | 2022-11-01 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001940A1 (es) | Composición farmacéutica que contiene un compuesto derivado de imidazo[1,5-a]indol, [1,2,4]triazolo[3,4-a]isoindol, [1,2,3]triazolo[5,1-a]isoindol ó 1,4-dihidroindeno[1,2-c] sustituidos y un segundo agente terapéutico; y su uso tratar la inmunosupresión mediada por indoleamina 2,3-dioxigenasa (ido), estimular la proliferación de células t, inhibir la degradación de triptófano en células que expresa ido, para tratar una enfermedad asociada con ido como una infección o cáncer (divisional de solicitud n° 2649-2015). | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CR20120313A (es) | Antagonistas de espiro-oxindol de mdm2 | |
| CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| CL2018000515A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015) | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
| GT201500248A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| PH12016500953A1 (en) | Tricyclic compounds as anticancer agents | |
| EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| TR201909582T4 (tr) | Pirimido[4,5-b]indol türevleri ve hematopoetik kök hücrelerinin ekspresyonunda bunlarin kullanimi. | |
| EA201101522A1 (ru) | Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10) | |
| GT200900328A (es) | Derivados de bencimidazol | |
| EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| GT201400043A (es) | Imidazopiridazinas sustituidas con amino | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
| CL2011002548A1 (es) | Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica. | |
| ECSP077989A (es) | Formulación de diclofenac y métodos para usarlas |